Skip to main content
. 2011 Sep 2;30(5):1926–1933. doi: 10.1007/s10637-011-9741-2

Table 2.

Incidence of grades 2, 3, and 4 toxicities possibly related to study treatment reported by ≥10% of patients

Eribulin initial dose level (mg/m2)
0.7 (n = 3) 1.0 (n = 3) 1.4 (n = 6) 2.0 (n = 3) Overall (N = 15)
Adverse event, n (%) G2 G3 G4 G2 G3 G4 G2 G3 G4 G2 G3 G4
Blood & lymphatic system disorders
 Febrile neutropenia 0 0 0 0 0 0 0 3 0 0 2 0 5
Metabolism & nutritional disorders
 Anorexia 0 0 0 0 0 0 1 0 0 0 1 0 2
Nervous system disorders
 Peripheral neuropathy 0 0 0 0 0 0 0 1 0 1 0 0 2
Skin & subcutaneous tissue disorders
 Alopecia 0 N/A N/A 0 N/A N/A 2 N/A N/A 1 N/A N/A 3
General disorders & administration-site conditions
 Fatigue 1 0 0 0 0 0 1 1 0 1 1 0 5
 Pyrexia 0 0 0 0 0 0 1 0 0 1 0 0 2
Investigations
 Neutropenia 0 0 0 1 1 0 0 1 5 0 1 2 11
 Leukopenia 0 0 0 2 1 0 0 4 2 0 2 1 12
 Lymphocytopenia 0 1 0 2 0 0 1 2 0 1 0 0 7
 Anemia 0 1 0 0 0 0 2 0 0 1 0 0 4
 Decreased hemoglobin 0 1 0 0 0 0 2 0 0 2 0 0 5
 Hyperglycemia 0 0 0 1 0 0 4 0 0 1 0 0 6
 Thrombocytopenia 0 0 0 1 0 0 1 0 0 0 0 0 2
 Increased AST 0 0 0 0 0 0 0 0 0 2 0 0 2
 Increased ALT 0 0 0 0 0 0 1 0 0 1 0 0 2

ALT alanine aminotransferase, AST aspartate aminotransferase, NA not applicable